Testing anti-HER2 treatment for HER2-enriched early breast cancer
Part of Cancer clinical trials.
This trial tests an anti-HER2 medicine in people whose breast cancer is classified as “HER2-enriched” using a special lab test (PAM50). It aims to see whether this treatment can help prevent or control cancer that cannot be fully removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that cannot be fully removed (unresectable) or has spread, but there is no confirmed distant metastasis on scans/biopsy
- Your cancer must be HER2-negative by lab testing (either IHC 1+ without ISH, or IHC 2+ with ISH showing negative results)
- You must have never received systemic (whole-body) treatment for stage II–III breast cancer
- You must be over 19 years old and be able to do study visits (ECOG 0–1, meaning fully active or limited but ambulatory)
- Your blood, kidney, liver, and heart tests must meet safety thresholds (including heart pumping strength with LVEF ≥ 50%)
- A tissue test must confirm your subtype is “HER2-enriched” by PAM50, and you must have available archived slides (FFPE slides)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests two study drugs, HLX22 and HLX87, together for people with HER2-positive breast cancer that has spread or come back. It may be an option if you haven't yet had chemotherapy or HER2-targeted therapy for advanced disease.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
Hear when a new HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.